Definitive Contract 75N93019C00051

Award Date 9/10/19
Potential Completion Date 9/24/26
Potential Value $151M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
New York, NY 10029, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This contract is part of the Collaborative Influenza Vaccine Innovation Centers (CIVIC) program, which aims to design and evaluate innovative influenza vaccine approaches. The contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), has a ceiling value of $150,567,831.64 and an ultimate completion date of September 24, 2026. The prime contractor is the Icahn School of Medicine at Mount Sinai (ISMMS), a renowned academic medical center in New York City. ISMMS has subcontracted with multiple universities and research organizations, including the University of Natural Resources and Life Sciences in Vienna, The Washington University, and Vivaldi Biosciences Inc., to provide a range of services such as bioprocess development, vaccine candidate testing, and production of GMP reagents. This contract does not use any set-aside designations. As part of the CIVIC program, this contract supports NIAID's efforts to advance influenza vaccine research and development.

Generated 9/25/24, 9:34 AM